Chem Biol 2001, 8:759–766.PubMedCrossRef 18. Yip-Schneider

MT, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks PA, Neelakantan S, Sweeney CJ, Schmidt CM: Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic RAD001 price cancer. Pancreas 2008, 37:e45-e53.PubMedCrossRef 19. Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther 2007, 6:1736–1744.PubMedCrossRef 20. Wang W, Adachi M, Zhang R, Zhou J, Zhu D: A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas 2009, 38:e114-e123.PubMedCrossRef 21. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 1998, 281:1322–1326.PubMedCrossRef 22. Gross A,

McDonnell JM, Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Gene Dev 1999, 13:1899–1911.PubMedCrossRef 23. Dong M, Zhou JP, Zhang H, Guo KJ, Tian YL, Dong YT: Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J G 2005, 11:2744–2747. 24. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 7-Cl-O-Nec1 clinical trial to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999, 19:5923–5929.PubMed 25. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE: NF-kB1 (p50) homodimers

contribute to transcription of the bcl-2 oncogene. J Biol Chem 2001, 276:45380–45386.PubMedCrossRef 26. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, Bours V: NF-kappa Unoprostone B2/p100 induces Bcl-2 expression. Leukemia 2003, 17:1349–1356.PubMedCrossRef 27. Catz SD, Johnson JL: Transcriptional regulation of Bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001, 20:7342–7345.PubMedCrossRef 28. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ: Targeting BCL-2 overexpression in various human malignancies through Nf-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmaco1 2005, 56:46–54.CrossRef 29. Salvesen GS, Dixit VM: Caspases: mtracellular signaling by proteolysis. Cell 1997, 91:443–446.PubMedCrossRef 30. Du C, Fang M, Li Y, Wang X, Smac A: Mitochondrial protein that promotes cytochrome-c dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:43–53.CrossRef 31. Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome-c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999, 274:11549–11556.PubMedCrossRef AZD5582 research buy competing interests The authors declare that they have no competing interests. Authors’ contributions JWL, MXC and YX carried out the molecular experiment and drafted the manuscript.